Home » Alliance Exploits New Genetic Research
Alliance Exploits New Genetic Research
CellCentric, a Cambridge company exploiting a critical area of genetic research, has won £250,000 funding that has triggered a commercial collaboration with Babraham Institute. CellCentric now has exclusive rights over epigenetic-related intellectual property generated at the Institute -- one of Europe's leading centers of excellence in this field of research.
Business Weekly (http://www.businessweekly.co.uk/news/view_article.asp?article_id=9321)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May